

Combination Therapies for Smoking Cessation



A Hierarchical Bayesian Meta-Analysis

Sarah B. Windle, MPH,¹ Kristian B. Fillion, PhD,^{1,2} Joseph G. Mancini, BSc,¹
Lauren Adye-White, BA&Sc,¹ Lawrence Joseph, PhD,^{2,3,4} Genevieve C. Gore, MLIS,⁵
Bettina Habib, MSc, MScPH,¹ Roland Grad, MD, MSc,^{6,7} Louise Pilote, MD, MPH, PhD,^{2,3,8}
Mark J. Eisenberg, MD, MPH^{1,2,9}

Context: Treatment guidelines recommend the use of combination therapies for smoking cessation, particularly behavioral therapy (BT) as an adjunct to pharmacotherapy. However, these guidelines rely on previous reviews with important limitations. This study's objective was to evaluate the efficacy of combination therapies compared with monotherapies, using the most rigorous data available.

Evidence acquisition: A systematic review and meta-analysis of RCTs of pharmacotherapies, BTs, or both were conducted. The Cochrane Library, Embase, PsycINFO, and PubMed databases were systematically searched from inception to July 2015. Inclusion was restricted to RCTs reporting biochemically validated abstinence at 12 months. Direct and indirect comparisons were made in 2015 between therapies using hierarchical Bayesian models.

Evidence synthesis: The search identified 123 RCTs meeting inclusion criteria (60,774 participants), and data from 115 (57,851 participants) were meta-analyzed. Varenicline with BT increased abstinence more than other combinations of a pharmacotherapy with BT (varenicline versus bupropion: OR=1.56, 95% credible interval [CrI]=1.07, 2.34; varenicline versus nicotine patch: OR=1.65, 95% CrI=1.10, 2.51; varenicline versus short-acting nicotine-replacement therapies: OR=1.68, 95% CrI=1.15, 2.53). Adding BT to any pharmacotherapy compared with pharmacotherapy alone was inconclusive, owing to wide CrIs (OR=1.17, CrI=0.60, 2.12). Nicotine patch with short-acting nicotine-replacement therapy appears safe and increases abstinence versus nicotine-replacement monotherapy (OR=1.63, CrI=1.06, 3.03). Data are limited concerning other pharmacotherapy combinations and their safety and tolerability.

Conclusions: Evidence suggests that combination therapy benefits may be less than previously thought. Combined with BT, varenicline increases abstinence more than other pharmacotherapy with BT combinations.

(Am J Prev Med 2016;51(6):1060–1071) © 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Context

Treatment guidelines, including those of the American Heart Association/American Stroke Association and the U.S. Public Health Service, recommend the use of behavioral therapy (BT) combined with

pharmacotherapy for smoking cessation.^{1,2} However, the guidelines are primarily based on a meta-analysis¹ with important limitations. These limitations include breaking the integrity of randomization by not restricting analyses first to within-study comparisons before making indirect

From the ¹Division of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital/McGill University, Montreal, Quebec, Canada; ²Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada; ³Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada; ⁴Research Institute, McGill University Health Centre, McGill University, Montreal, Quebec, Canada; ⁵Schulich Library of Science and Engineering, McGill University, Montreal, Quebec, Canada; ⁶Herzl Family Practice Centre, Jewish General Hospital, Montreal, Quebec, Canada; ⁷Department of Family Medicine,

McGill University, Montreal, Quebec, Canada; ⁸Division of General Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada; and ⁹Division of Cardiology, Jewish General Hospital, Montreal, Quebec, Canada

Address correspondence to: Mark J. Eisenberg, MD, MPH, Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital/McGill University, 3755 Côte Ste-Catherine Road, Suite H-421.1, Montreal, Quebec, Canada H3T 1E2. E-mail: mark.eisenberg@ladydavis.ca
0749-3797/\$36.00

<http://dx.doi.org/10.1016/j.amepre.2016.07.011>

comparisons between studies (to properly produce ratios of ORs), and not considering whether or not participants also received pharmacotherapy (i.e., data from trials that included pharmacotherapy were pooled with data from trials that did not include pharmacotherapy). Package inserts for first-line smoking-cessation therapies (i.e., nicotine replacement therapies [NRTs], bupropion, and varenicline) likewise recommend adjunctive counseling.^{3–6} These recommendations are supported by a Cochrane review, which found a modest increase in abstinence with combined pharmacotherapy and BT versus pharmacotherapy alone.⁷ However, this Cochrane review included trials with < 12 months of follow-up and those that did not biochemically validate abstinence. A systematic review and meta-analysis of RCTs was therefore conducted to examine the long-term efficacy of combination therapies versus monotherapies, using RCTs with ≥ 12 months of follow-up that biochemically validated smoking abstinence.

Evidence Acquisition

The systematic review and meta-analysis was performed according to a prespecified protocol (PROSPERO #CRD42014007105) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.⁸

Search Strategy

Designed by an experienced medical liaison librarian (GG), searches of the Cochrane Library, PubMed, Ovid Embase, and Ovid PsycINFO databases were conducted in July 2015, with no publication date restrictions. Searches were conducted using Medical Subject Headings in PubMed and the Cochrane Library, Emtree terms in Embase, Psychological Index Terms in PsycINFO, and keywords in all databases. Briefly, search terms included *smoking cessation, combination therapy, pharmacotherapy, behavioral therapy, bupropion, varenicline, and nicotine replacement therapy*. Hedges were used in PubMed,⁹ Embase,¹⁰ and PsycINFO¹¹ to filter results to RCTs and systematic reviews (full search strategies in [Appendix A](#), available online).

Study Selection

Titles and abstracts of articles identified by the search were screened; any article deemed potentially relevant was carried forward for full-text review. Full-text screening was conducted independently by two reviewers (JGM and LAW), with disagreements resolved by consensus or a third reviewer (SBW). Eligibility was assessed using prespecified inclusion and exclusion criteria, as described below.

Included studies were restricted to RCTs in which at least one first-line smoking-cessation therapy (NRT, bupropion, varenicline, or BT) was compared with at least one other first-line cessation therapy or placebo (or usual care in trials of BT alone). NRTs included nicotine patch and short-acting NRTs such as nicotine gum, inhaler, nasal spray, lozenge, tablet, and mouth spray. For the purposes of this study, BT was defined as the

provision of verbal instructions with the intention of modifying a health-related behavior, which in this case was smoking. This definition encompassed minimal clinical interventions (e.g., brief advice to stop smoking from a healthcare worker), individual counseling, group counseling, and telephone counseling. To be considered for inclusion, RCTs also had to report biochemically validated seven-day point prevalence smoking abstinence at 12 months or continuous smoking abstinence at 12 months. Seven-day point prevalence abstinence describes an individual's smoking status based on the seven days prior to the follow-up visit. If, during the 12-month visit, an individual reports to not have smoked in the past seven days and this self-report is confirmed by a biochemical test conducted during the visit (e.g., exhaled carbon monoxide or cotinine tests), the individual is considered abstinent according to this definition. Continuous abstinence, on the other hand, was defined by biochemically validated self-report of complete abstinence at all follow-ups. Typically, to be considered continuously abstinent, participants must have completed all follow-up visits. RCTs also had to be published in English or French, and report data from a sample of cigarette smokers motivated to quit. Studies without a statement concerning motivation to quit were assumed to meet this criterion. Exclusion criteria included abstract or conference proceedings; cluster randomization; trials conducted exclusively in light smokers (fewer than ten cigarettes/day); and trials of nicotine e-cigarettes, as these are not approved for use in smoking cessation.

Data Abstraction and Quality Assessment

Two individuals (JGM and LAW) independently abstracted data, with disagreements resolved by consensus or a third reviewer (SBW). Data were abstracted concerning study characteristics and outcomes. RCT quality was evaluated in duplicate using the Cochrane Collaboration's Tool for Assessing Risk of Bias.¹²

Statistical Analysis

The meta-analysis used Bayesian hierarchical random-effects meta-analytic models to estimate ORs and credible intervals (CrIs), the Bayesian analogue of CIs. This process involved both direct and indirect comparisons of smoking-cessation treatments. Direct comparisons involved RCTs in which participants were randomized to the treatments being compared. Data were pooled for direct comparisons that were examined in four or more RCTs; having three or fewer studies was considered insufficient to reasonably estimate between-study variance in a random-effects model. To facilitate comparisons, all BTs were grouped together for some analyses. Likewise, some analyses grouped short-acting NRTs (i.e., all NRTs except nicotine patch), all NRTs, or all pharmacotherapies. Placebo used in combination with another therapy was assumed to perform similarly to combinations that used the same therapy without adding placebo.

Indirect comparisons then allowed comparisons of therapies not directly compared in RCTs. In general, if one set of trials compared intervention A to intervention B, and another set of trials compared intervention B to intervention C, then an indirect comparison can be created that compares A to C through common comparator B. These indirect comparisons were created by estimating ORs for A versus B and B versus C using the Bayesian hierarchical meta-analytic models; the first was then divided by the

second, leading to a ratio of ORs (Appendix B, available online, describes additional meta-analytic model details). All statistical analyses were conducted in 2015, following systematic literature searches and data extraction.

Evidence Synthesis

Study and Patient Characteristics

The database search yielded 14,998 records, with two records identified from other sources (Figure 1). After removing duplicates and screening titles and abstracts, 587 articles underwent full-text review, of which 123 met the predefined inclusion criteria (60,774 participants).^{13–135} These trials were conducted primarily in the general population (93 trials), and most trials recruited participants from North America, Europe, Australia/New Zealand, or some combination of these regions (117 trials). Included trials were published between 1983 and 2015 (median, 2002) and enrolled 51–3,684 participants (median, 303 participants) (detailed characteristics are provided in Appendix C, available online).

Of the 123 trials, data from 115 (57,851 participants) were included in the meta-analysis. Trials were excluded from the meta-analysis if they examined a combination of therapies for which there was an insufficient number

of other studies to pool. Some trials were unable to be included owing to the merging of BTs together (e.g., a treatment arm of nicotine patch with both group and individual counseling would be considered the same as the control arm of nicotine patch with only individual counseling). Risk of bias was largely considered low or uncertain across trials for all categories (86%–98%) except blinding (58%) (Appendix D, available online). This risk of bias in blinding was primarily due to BT use in many trials, where blinding to treatment allocation was impossible. Among trials that did not include BT, the risk of bias in blinding was judged low or uncertain in all trials.

Pharmacotherapy With Behavioral Therapy Combinations

Fourteen direct comparisons were performed of smoking-cessation therapy combinations and monotherapies, including ten of BT combinations (Appendix E, available online). Results showed that any pharmacotherapy (nicotine patch, short-acting NRT, bupropion, or varenicline) combined with BT increased abstinence at 12 months versus BT alone (Figure 2A–D). These direct comparisons were supplemented by indirect comparisons, which found that varenicline with BT was more efficacious than all other combinations of a




Figure 1. PRISMA flow diagram.




Figure 2. Pharmacotherapy + behavioral therapy versus behavioral therapy for smoking cessation at 12 months. **(A)** Nicotine patch + behavioral therapy versus behavioral therapy. **(B)** Short-acting NRT + behavioral therapy versus behavioral therapy. **(C)** Bupropion + behavioral therapy versus behavioral therapy. **(D)** Varenicline + behavioral therapy versus behavioral therapy.

BT, behavioral therapy; SA-NRT, short-acting nicotine replacement therapy

pharmacotherapy with BT (varenicline versus bupropion, OR=1.56, 95% CrI=1.07, 2.34; varenicline versus nicotine patch: OR=1.65, 95% CrI=1.10, 2.51; varenicline versus short-acting NRTs: OR=1.68, 95% CrI=1.15, 2.53), which performed similarly to each other (Table 1).

When combination pharmacotherapy with BT was compared with pharmacotherapy alone, long-term abstinence was similar between groups (Appendix F, available online). However, the CrIs were wide (e.g., OR=1.17, CrI=0.60, 2.12, for any pharmacotherapy with BT versus pharmacotherapy alone), likely owing to the small number of studies ($n=7$) included in this comparison. Moreover, results indicated that higher-intensity BT (i.e., individual, group, or telephone counseling) versus minimal clinical intervention did not increase abstinence in individuals prescribed a pharmacotherapy (Appendix G, available online). Likewise, a sensitivity analysis was conducted of any comparison of intensive BT versus minimal clinical intervention, regardless of adjunctive therapies, which also found no difference between groups (data not shown).

Using the most rigorous data available, this meta-analysis did not find strong evidence that BT is a necessary adjunct to pharmacotherapy, although the CrIs were wide. However, when used with BT, varenicline increased abstinence more than all other combinations of a pharmacotherapy with BT.

Pharmacotherapy With Pharmacotherapy Combinations

Data concerning the combination of two or more pharmacotherapies are limited. When all trials of combined NRTs were pooled, there was greater abstinence with combination therapy than with NRT monotherapy (OR=1.63, CrI=1.06, 3.03) (Figure 3A). All of these trials combined the nicotine patch with a short-acting NRT (three trials with gum, two with the inhaler, and one each with the nasal spray or mouth spray), compared with either the nicotine patch or a short-acting NRT alone. When the analysis was restricted to NRT combinations versus nicotine patch alone, the addition of a short-acting

Table 1. Indirect Comparisons of Smoking-Cessation Therapy Efficacy With Respect to Smoking Abstinence

Treatment group	Referent group					
	Usual care	BT	Nicotine patch + BT	Short-Acting NRT + BT	Bupropion + BT	Varenicline + BT
Usual care	1.00	0.47 ^a (0.29, 0.72)	0.27 (0.16, 0.43)	0.27 (0.17, 0.43)	0.25 (0.15, 0.40)	0.16 (0.09, 0.28)
BT	2.12 ^a (1.38, 3.39)	1.00	0.55 ^b (0.42, 0.68)	0.58 ^c (0.49, 0.68)	0.55 ^d (0.46, 0.64)	0.34 ^e (0.23, 0.49)
Nicotine patch + BT	3.73 (2.30, 6.28)	1.81 ^b (1.47, 2.37)	1.00	1.02 (0.78, 1.36)	0.94 (0.72, 1.26)	0.61 (0.40, 0.91)
Short-acting NRT + BT	3.65 (2.31, 6.01)	1.73 ^c (1.47, 2.04)	0.99 (0.74, 1.28)	1.00	0.93 (0.73, 1.17)	0.60 (0.40, 0.87)
Bupropion + BT	3.94 (2.48, 6.55)	1.83 ^d (1.56, 2.18)	1.06 (0.79, 1.38)	1.08 (0.85, 1.37)	1.00	0.64 (0.43, 0.94)
Varenicline + BT	6.17 (3.54, 11.19)	2.96 ^e (2.04, 4.44)	1.65 (1.10, 2.51)	1.68 (1.15, 2.53)	1.56 (1.07, 2.34)	1.00

Note: All data are presented as OR (95% CrI). Results in italics are direct comparisons on which the indirect comparisons are based. The referent group of each comparison is represented by the header of the column the result is listed under. Results to the right of the diagonal are the inverse of the results to the left of the diagonal. For example, in comparing Nicotine Patch + BT versus BT alone, Nicotine Patch + BT seems more effective in achieving smoking abstinence than BT alone, with an OR of 1.81, CrI 1.47, 2.37. The referent group in this comparison is BT alone. This can also be thought of as BT being less effective than the combination Nicotine Patch + BT, with an OR of 0.55, CrI 0.42, 0.68. In this comparison, the referent group is Nicotine Patch + BT.

^aEstimates are based on the meta-analysis of 17 RCTs.

^bEstimates are based on the meta-analysis of 15 RCTs.

^cEstimates are based on the meta-analysis of 29 RCTs.

^dEstimates are based on the meta-analysis of 20 RCTs.

^eEstimates are based on the meta-analysis of 14 RCTs.

BT, behavioral therapy; CrI, credible interval; NRT, nicotine replacement therapy; short-acting NRT, any NRT (e.g., gum, inhaler) except nicotine patch.

NRT to the nicotine patch did not increase long-term abstinence (Figure 3B). However, the CrIs were wide, and the possibility of a difference cannot be excluded. Likewise, the combination of bupropion with NRT(s) did not increase abstinence; however, the comparison arms (e.g., bupropion monotherapy, NRT monotherapy) varied (Figure 3C).

In an additional analysis, all 12 trials that examined the efficacy of adding an additional pharmacotherapy to one or more pharmacotherapies were pooled (Figure 3D). Results showed an increase in abstinence with the use of an additional pharmacotherapy. Most trials of combination pharmacotherapies included adjunctive BT in both arms; sensitivity analyses that excluded trials without BT did not substantively alter the findings (data not shown). Overall, data concerning combination pharmacotherapies are limited, with the available evidence suggesting the combination of nicotine patch and a short-acting NRT is more efficacious than NRT monotherapy.

Safety and Tolerability

Data available regarding the safety and tolerability of combination pharmacotherapies are limited. The reporting and occurrence of serious adverse events (SAEs), including death, was rare (Appendices H and I, available online). Only six of the 12 trials examining combination pharmacotherapy versus monotherapy reported SAEs by treatment arm, of which there were 19 total in 2,392 participants (0.8%).^{22,30,37,39,70,121} Six studies also specifically reported the number of deaths (or it was inferred from zero reported SAEs), of which there were six in 1,582 participants (0.4%).^{21,30,37,39,113,121} SAEs and deaths appear to be similar between pharmacotherapy combination and monotherapy arms; however, the available RCTs were not powered to detect differences in these events. There was one report of attempted suicide in a trial of combination varenicline with bupropion; however, it occurred in the varenicline monotherapy arm, and there were no other reports of serious neuropsychiatric events.³⁷ No SAEs were considered to be related to any smoking-cessation pharmacotherapy.

The overall incidence of adverse events (AEs) and participant withdrawal due to AEs was rarely reported (Appendices H and I, available online). However, some trials included a summary statement about AEs and/or the incidence of specific AEs. In trials assessing the nicotine patch with short-acting NRT, AEs were considered to be mild, tolerable, and generally similar between groups.^{22,24,30,73,95} Among trials that examined




Figure 3. Combined pharmacotherapies versus monotherapies for smoking cessation at 12 months. (A) NRT + NRT versus NRT. (B) Nicotine patch + NRT versus nicotine patch. (C) Bupropion + NRT versus monotherapy. (D) Drug + drug versus drug. Note: One included trial (Evans 2007³⁹) compared a three-drug combination to a two-drug combination. NRT, nicotine replacement therapy; SA-NRT, short-acting nicotine replacement therapy; Drug, any pharmacotherapy.

bupropion with NRTs, reported rates of treatment discontinuation were similar between combination therapy and monotherapy groups, and no AEs were consistently reported more frequently in the combination therapy group across studies.^{39,70,113} A single trial (506 participants) had a combined bupropion and varenicline group versus varenicline alone.³⁷ In this trial, the combination therapy group had a higher rate of anxiety (7.2% versus 3.1%) and depressive symptoms (3.6% versus 0.8%) compared with the varenicline monotherapy group. All other AEs were similar between groups.

Discussion

This study was designed to assess the efficacy of combination therapy versus monotherapy for smoking cessation. Results demonstrated that among pharmacotherapy with BT combinations, varenicline increased

long-term abstinence more than either bupropion or NRTs. When examining the most rigorous data available, no strong evidence was found that BT is a necessary adjunct to pharmacotherapy. Among combination pharmacotherapies, nicotine patch with a short-acting NRT appears safe and more efficacious than NRT monotherapy. Other combination pharmacotherapies may be efficacious, but available evidence is insufficient to make specific recommendations for their use at this time.

Combination therapies for smoking cessation have been examined previously. However, these reviews did not restrict inclusion to trials with ≥ 12 months of follow-up nor require biochemical validation of abstinence.^{136–141} Consistent findings include the superiority of varenicline over bupropion^{136,137} and the similar performance of bupropion and NRTs, when pharmacotherapies are combined with BT.^{136,137} Some of the present findings contradict a Cochrane review conducted in 2012,⁷ and the review

on which the U.S. Public Health Service clinical practice guideline for treating tobacco use and dependence and the American Heart Association/American Stroke Association stroke prevention guidelines are based.¹

The Cochrane review found an increase in abstinence with combined pharmacotherapy and BT versus pharmacotherapy alone (relative risk [RR]=1.25, 95% CI=1.08, 1.45). The review also found a small increase in abstinence with higher-intensity versus lower-intensity adjunctive BT (RR=1.16, 95% CI=1.09, 1.24). The discordance between these results and those of the present study is likely attributable to the Cochrane review's inclusion of trials with <12 months of follow-up. The efficacy of smoking-cessation interventions declines over time; therefore, including studies of shorter durations likely resulted in an overestimate of long-term efficacy. Moreover, the Cochrane review included trials not biochemically validating abstinence. In their sensitivity analysis, the review found the point estimate for abstinence with higher-intensity versus lower-intensity adjunctive BT was attenuated when trials not using biochemical validation were excluded (RR=1.09, 95% CI=0.99, 1.21). This is consistent with studies that have shown that smoking prevalence is underestimated when based solely on self-report.¹⁴² The requirement of biochemical validation of abstinence as an inclusion criterion was meant to prevent such bias in the current study.

Several guidelines are based on a meta-analysis¹ conducted for the U.S. Public Health Service, which suggested a strong dose-response for BTs; however, it had important limitations. These limitations include not restricting analyses first to within-study comparisons before making indirect comparisons between studies (to properly produce ratios of ORs), and pooling data from trials that included pharmacotherapy with data from those that did not include pharmacotherapy. These limitations make it difficult to draw conclusions from this review, despite its use in guidelines to support the use of BT with pharmacotherapy. Using the most rigorous evidence available, the current meta-analysis was unable to draw definitive conclusions about the necessity of adjunctive BT in users of pharmacotherapy.

There is a strong underlying rationale to suggest that pharmacotherapy combinations could increase abstinence. Although the mechanism for NRTs is the same across delivery methods, a short-acting NRT can be used to relieve acute cravings in users of the nicotine patch. Indeed, a previous review of NRTs found that the combination of nicotine patch and short-acting NRT increased abstinence versus NRT monotherapy¹³⁷; this meta-analysis suggests that this remains true through ≥ 1 year in biochemically validated trials.

The unique mechanisms of action of both bupropion and varenicline make these drugs potential candidates for use in

combination with NRTs or with each other. A previous review found combination bupropion with NRT to be modestly more efficacious than bupropion alone (RR=1.24, 95% CI=1.06, 1.45)¹³⁷; both this review (OR=1.23, CrI=0.52, 2.88) and a recent review of antidepressants (including bupropion) for smoking cessation (RR=1.19, 95% CI=0.94, 1.51)¹³⁷ did not find an increase in abstinence, although the point estimates were similar. This difference likely reflects the use of a fixed-effects model in the NRT review, versus the random-effects models used in the other analyses. This review and a previous review of nicotine receptor partial agonists¹³⁷ did not identify any eligible trials of varenicline in combination with NRT, a practice that is not recommended by the manufacturer based on an increase in side effects in a small, unpublished study.³

No previous reviews specifically considered the occurrence of AEs with combination pharmacotherapies versus a single drug alone.^{136,137} The data from the current review, particularly for combination NRTs, suggest that combinations are safe and tolerable. Safety and tolerability data remain limited for other combination therapies, including bupropion and varenicline, which have the potential for a favorable risk-benefit ratio.

Limitations

This study had several potential limitations. First, when pooling data across trials, there is the potential for heterogeneity in study design, population, and interventions. This is particularly true for BTs, for which varying modes and intensities were grouped in the meta-analysis. However, given the heterogeneity between included trials in the intensity and duration of BTs, the authors chose to group them to facilitate the analysis. Although the inclusion of minimal clinical interventions with more intensive BTs may, in theory, dilute treatment effects, the authors previously showed that all BTs, regardless of their intensity, have similar smoking abstinence effects at 12 months.¹⁴³ In addition, random-effects models that accounted for both between- and within-study heterogeneity were employed. Moreover, several subgroup analyses were conducted to explicitly examine sources of this heterogeneity. Second, the grouping of minimal clinical intervention with more intensive modes of BT does not account for the fact that such briefly provided advice and support is now routinely offered to smokers as part of routine care, whether or not they receive some other form of cessation therapy. However, it is for this reason that such interventions were provided as part of the standard of care in many of the more recent trials included in this study. Third, a limitation inherent in indirect comparisons is the assumption that the effects of interest are constant across trials (e.g., when indirectly comparing A versus B and B versus C, the assumption is

that the effect of B is constant). The absolute treatment effects (i.e., the proportion of abstinent participants) were examined for therapies that were treated as constant for the purposes of indirect comparisons, and the assumption was found to be valid (i.e., there were no large differences between comparators). Fourth, many of the treatment comparisons of interest were examined in a limited number of trials, in part because of the use of strict inclusion criteria requiring biochemically validated smoking abstinence at ≥ 12 months. This therefore reduced the number of eligible RCTs and impacted the precision of estimates. However, by decreasing potential misclassification of smoking status, the results have increased validity compared with reviews that did not require biochemical validation. The strict inclusion criteria may have also impacted the availability of data concerning safety and tolerability, which were limited.

Conclusions

This meta-analysis of combination therapies for smoking cessation found several key differences compared with previous reviews. With inclusion restricted to evidence from long-term, biochemically validated trials, this meta-analysis suggests that the benefits of combination behavioral and pharmacotherapy may be less than previously thought. Varenicline with BT increased abstinence more than all other combinations of a pharmacotherapy with BT. If NRT is desired, the combination of nicotine patch and a short-acting NRT should be recommended above a single NRT. There is currently insufficient evidence to recommend combination pharmacotherapies that include bupropion or varenicline.

This project was funded by a grant from the Canadian Institutes of Health Research (CIHR; KRS-126599). Dr. Filion holds a CIHR New Investigator Award.

Dr. Eisenberg is the Principal Investigator of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) trial (NCT00794573), an investigator-initiated trial, which received funding and study drug/placebo from Pfizer Inc. Pfizer Inc. had no role in the design, conduct, analysis, interpretation of data, or reporting of the EVITA trial. Dr. Eisenberg also received honoraria from Pfizer Inc. for providing continuing medical education on smoking cessation.

No other financial disclosures were reported by the authors of this paper.

References

1. Fiore M, Tobacco Use and Dependence Guideline Panel. *Treating Tobacco Use and Dependence: 2008 Update*. Rockville, MD: U.S. DHHS, Public Health Service; 2008.
2. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014;45(12):3754–3832. <http://dx.doi.org/10.1161/STR.0000000000000046>.
3. Pfizer Canada Inc. Champix product monograph. www.pfizer.ca/en/our_products/products/monograph/152. Published 2014. Accessed February 9, 2015.
4. GlaxoSmithKline. Zyban prescribing information. www.gsksource.com/gskprm/htdocs/documents/ZYBAN-PI-MG.PDF. Published 2014. Accessed February 9, 2015.
5. Pfizer. Nicotrol inhaler prescribing information. www.pfizer.com/files/products/uspi_nicotrol_inhaler.pdf. Published 2008. Accessed February 9, 2015.
6. Pfizer. Nicotrol nasal spray prescribing information. www.pfizer.com/files/products/uspi_nicotrol.pdf. Published 2010. Accessed February 9, 2015.
7. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. *Cochrane Database Syst Rev*. 2012;12:CD009670. <http://dx.doi.org/10.1002/14651858.cd009670.pub2>.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg*. 2009;8(5):336–341. <http://dx.doi.org/10.1016/j.ijsu.2010.02.007>.
9. U.S. National Library of Medicine. PubMed subject filters: search strategy used to create the systematic reviews subset on PubMed. www.nlm.nih.gov/bsd/pubmed_subsets/sysreviews_strategy.html. Accessed April 12, 2013.
10. Cochrane Central Register of Controlled Trials. www.cochrane.org/editorial-and-publishing-policy-resource/cochrane-central-register-controlled-trials-central. Published 2014. Accessed April 16, 2014.
11. Eady AM, Wilczynski NL, Haynes RB. PsycINFO search strategies identified methodologically sound therapy studies and review articles for use by clinicians and researchers. *J Clin Epidemiol*. 2008;61(1):34–40. <http://dx.doi.org/10.1016/j.jclinepi.2006.09.016>.
12. Higgins J, Green S, eds., The Cochrane Collaboration. *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester, UK: Wiley-Blackwell; 2008. <http://dx.doi.org/10.1002/9780470712184>.
13. Albrecht SA, Caruthers D, Patrick T, et al. A randomized controlled trial of a smoking cessation intervention for pregnant adolescents. *Nurs Res*. 2006;55(6):402–410. <http://dx.doi.org/10.1097/00006199-200611000-00004>.
14. Alterman AI, Gariti P, Mulvaney F. Short- and long-term smoking cessation for three levels of intensity of behavioral treatment. *Psychol Addict Behav*. 2001;15(3):261–264. <http://dx.doi.org/10.1037/0893-164X.15.3.261>.
15. Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med*. 2013;159(6):390–400. <http://dx.doi.org/10.7326/0003-4819-159-6-201309170-00005>.
16. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax*. 2008;63(8):717–724. <http://dx.doi.org/10.1136/thx.2007.090647>.
17. Baker AL, Richmond R, Kay-Lambkin FJ, et al. Randomized controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders. *Nicotine Tob Res*. 2015;17(8):946–954. <http://dx.doi.org/10.1093/ntr/ntv039>.
18. Bakkevig O, Steine S, von Hagenbrad K, Laerum E. Smoking cessation. A comparative, randomised study between management in general practice and the behavioural programme SmokEnders. *Scand J Prim Health Care*. 2000;18(4):247–251. <http://dx.doi.org/10.1080/028134300448832>.
19. Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. *Arch Intern Med*. 1989;149(8):1818–1821. <http://dx.doi.org/10.1001/archinte.1989.00390080080018>.

20. Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. *Eur Respir J*. 1997;10(7):1585–1590. <http://dx.doi.org/10.1183/09031936.97.10071585>.
21. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. *BMJ*. 1999;318(7179):285–288. <http://dx.doi.org/10.1136/bmj.318.7179.285>.
22. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med*. 2000;160(20):3128–3134. <http://dx.doi.org/10.1001/archinte.160.20.3128>.
23. Brown RA, Niaura R, Lloyd-Richardson EE, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. *Nicotine Tob Res*. 2007;9(7):721–730. <http://dx.doi.org/10.1080/14622200701416955>.
24. Caldwell BO, Adamson SJ, Crane J. Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation. *Nicotine Tob Res*. 2014;16(10):1356–1364.
25. Campbell IA, Lyons E, Prescott RJ. Stopping smoking. Do nicotine chewing-gum and postal encouragement add to doctors' advice. *Practitioner*. 1987;231(1423):114–117.
26. Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. *Respir Med*. 1991;85(2):155–157. [http://dx.doi.org/10.1016/S0954-6111\(06\)80295-7](http://dx.doi.org/10.1016/S0954-6111(06)80295-7).
27. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. *Respir Med*. 1996;90(1):47–51. [http://dx.doi.org/10.1016/S0954-6111\(96\)90244-9](http://dx.doi.org/10.1016/S0954-6111(96)90244-9).
28. Christenhusz L, Pieterse M, Seydel E, van der Palen J. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. *Patient Educ Couns*. 2007;66(2):162–166. <http://dx.doi.org/10.1016/j.pec.2006.11.006>.
29. Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. *J Consult Clin Psychol*. 1996;64(2):314–323. <http://dx.doi.org/10.1037/0022-006X.64.2.314>.
30. Cooney NL, Cooney JL, Perry BL, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. *Addiction*. 2009;104(9):1588–1596. <http://dx.doi.org/10.1111/j.1360-0443.2009.02624.x>.
31. Cooper TV, Klesges RC, Debon MW, Zbikowski SM, Johnson KC, Clemens LH. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. *Addict Behav*. 2005;30(1):61–75. <http://dx.doi.org/10.1016/j.addbeh.2004.04.013>.
32. Crofton J, Campbell IA, Cole PV. Comparison of four methods of smoking withdrawal in patients with smoking related diseases. *Br Med J*. 1983;286(6365):595–597. <http://dx.doi.org/10.1136/bmj.286.6365.595>.
33. Cropsey KL, Clark CB, Zhang XN, Hendricks PS, Jardin BF, Lahti AC. Race and medication adherence moderate cessation outcomes in criminal justice smokers. *Am J Prev Med*. 2015;49(3):335–344. <http://dx.doi.org/10.1016/j.amepre.2015.03.014>.
34. Curry SJ, Ludman EJ, Graham E, Stout J, Grothaus L, Lozano P. Pediatric-based smoking cessation intervention for low-income women: a randomized trial. *Arch Pediatr Adolesc Med*. 2003;157(3):295–302. <http://dx.doi.org/10.1001/archpedi.157.3.295>.
35. Curry SJ, Marlatt GA, Gordon J, Baer JS. A comparison of alternative theoretical approaches to smoking cessation and relapse. *Health Psychol*. 1988;7(6):545–556. <http://dx.doi.org/10.1037/0278-6133.7.6.545>.
36. Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. *Arch Fam Med*. 1998;7(5):425–430. <http://dx.doi.org/10.1001/archfam.7.5.425>.
37. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA*. 2014;311(2):155–163. <http://dx.doi.org/10.1001/jama.2013.283185>.
38. Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. *J Am Coll Cardiol*. 2013;61(5):524–532. <http://dx.doi.org/10.1016/j.jacc.2012.08.1030>.
39. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol*. 2007;27(4):380–386. <http://dx.doi.org/10.1097/01.jcp.0b013e3180ca86fa>.
40. Feeney GFX, McPherson A, Connor JP, McAlister A, Young RM, Garrahy P. Randomized controlled trial of two cigarette quit programmes in coronary care patients after acute myocardial infarction. *Intern Med J*. 2001;31(8):470–475. <http://dx.doi.org/10.1046/j.1445-5994.2001.00110.x>.
41. Fiore MC, McCarthy DE, Jackson TC, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. *Prev Med*. 2004;38(4):412–420. <http://dx.doi.org/10.1016/j.ypmed.2003.11.002>.
42. Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. *Arch Intern Med*. 2007;167(16):1791–1797. <http://dx.doi.org/10.1001/archinte.167.16.1791>.
43. Fowler G. Randomised trial of nicotine patches in general practice: results at one year. *Br Med J*. 1994;308(6942):1476–1477. <http://dx.doi.org/10.1136/bmj.308.6942.1476>.
44. Garcia MP, Becona E. Evaluation of the amount of therapist contact in a smoking cessation program. *Span J Psychol*. 2000;3(1):28–36. <http://dx.doi.org/10.1017/S1138741600005515>.
45. Garvey AJ, Kinnunen T, Nordstrom BL, et al. Effects of nicotine gum dose by level of nicotine dependence. *Nicotine Tob Res*. 2000;2(1):53–63. <http://dx.doi.org/10.1080/14622200050011303>.
46. Gifford EV, Kohlenberg BS, Hayes SC, et al. Does acceptance and relationship focused behavior therapy contribute to bupropion outcomes? A randomized controlled trial of functional analytic psychotherapy and acceptance and commitment therapy for smoking cessation. *Behav Ther*. 2011;42(4):700–715. <http://dx.doi.org/10.1016/j.beth.2011.03.002>.
47. Gilbert JR, Wilson DM, Best JA, et al. Smoking cessation in primary care. A randomized controlled trial of nicotine-bearing chewing gum. *J Fam Pract*. 1989;28(1):49–55.
48. Ginsberg D, Hall SM, Rosinski M. Partner support, psychological treatment, and nicotine gum in smoking treatment: an incremental study. *Int J Addict*. 1992;27(5):503–514. <http://dx.doi.org/10.3109/10826089209063465>.
49. Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study. *Croat Med J*. 2003;44(2):219–224.
50. Glover ED, Glover PN, Franzon M, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. *Nicotine Tob Res*. 2002;4(4):441–450. <http://dx.doi.org/10.1080/146222002100018443>.
51. Gonzales D, Hajek P, Pliamm L, et al. Re-treatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. *Clin Pharmacol Ther*. 2014;96(3):390–396. <http://dx.doi.org/10.1038/clpt.2014.124>.
52. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):47–55. <http://dx.doi.org/10.1001/jama.296.1.47>.

53. Gritz ER, Danysh HE, Fletcher FE, et al. Long-term outcomes of a cell phone-delivered intervention for smokers living with HIV/AIDS. *Clin Infect Dis*. 2013;57(4):608–615. <http://dx.doi.org/10.1093/cid/cit349>.
54. Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. *Addiction*. 2009;104(6):1043–1052. <http://dx.doi.org/10.1111/j.1360-0443.2009.02548.x>.
55. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. *Arch Gen Psychiatry*. 2002;59(10):930–936. <http://dx.doi.org/10.1001/archpsyc.59.10.930>.
56. Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT. Nicotine gum and behavioral treatment: a placebo controlled trial. *J Consult Clin Psychol*. 1987;55(4):603–605. <http://dx.doi.org/10.1037/0022-006X.55.4.603>.
57. Hennrikus DJ, Lando HA, McCarty MC, et al. The TEAM project: the effectiveness of smoking cessation intervention with hospital patients. *Prev Med*. 2005;40(3):249–258. <http://dx.doi.org/10.1016/j.ypmed.2004.05.030>.
58. Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. *Chest*. 1995;108(2):447–451. <http://dx.doi.org/10.1378/chest.108.2.447>.
59. Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. *Int J Tuberc Lung Dis*. 2012;16(2):268–272. <http://dx.doi.org/10.5588/ijtld.11.0183>.
60. Hill RD, Rigdon M, Johnson S. Behavioral smoking cessation treatment for older chronic smokers. *Behav Ther*. 1993;24(2):321–329. [http://dx.doi.org/10.1016/S0005-7894\(05\)80272-2](http://dx.doi.org/10.1016/S0005-7894(05)80272-2).
61. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. *Arch Intern Med*. 1994;154(22):2567–2572. <http://dx.doi.org/10.1001/archinte.1994.00420220059007>.
62. Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O. The nicotine inhaler in smoking cessation. *Arch Intern Med*. 1997;157(15):1721–1728. <http://dx.doi.org/10.1001/archinte.1997.00440360143016>.
63. Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R. Efficacy of bupropion in the indigenous Maori population in New Zealand. *Thorax*. 2005;60(2):120–123. <http://dx.doi.org/10.1136/thx.2004.030239>.
64. Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML. Nicotine vs placebo gum in general medical practice. *JAMA*. 1989;261(9):1300–1305. <http://dx.doi.org/10.1001/jama.1989.03420090064032>.
65. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? *Nicotine Tob Res*. 1999;1(2):169–174. <http://dx.doi.org/10.1080/14622299050011281>.
66. Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. *JAMA*. 1994;271(8):595–600. <http://dx.doi.org/10.1001/jama.1994.03510320035026>.
67. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med*. 1997;337(17):1195–1202. <http://dx.doi.org/10.1056/NEJM199710233371703>.
68. Jensen EJ, Schmidt E, Pedersen B, Dahl R. Effect of nicotine, silver acetate, and ordinary chewing gum in combination with group counselling on smoking cessation. *Thorax*. 1990;45(11):831–834. <http://dx.doi.org/10.1136/thx.45.11.831>.
69. Jorenby DE, Hays J, Rigotti NA, et al. Efficacy of varenicline, an 42 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):56–63. <http://dx.doi.org/10.1001/jama.296.1.56>.
70. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med*. 1999;340(9):685–691. <http://dx.doi.org/10.1056/NEJM199903043400903>.
71. Killen JD, Fortmann SP, Davis L, Varady A. Nicotine patch and self-help video for cigarette smoking cessation. *J Consult Clin Psychol*. 1997;65(4):663–672. <http://dx.doi.org/10.1037/0022-006X.65.4.663>.
72. Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. *J Consult Clin Psychol*. 1990;58(1):85–92. <http://dx.doi.org/10.1037/0022-006X.58.1.85>.
73. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med*. 1995;24(1):41–47. <http://dx.doi.org/10.1006/pmed.1995.1006>.
74. Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. *Am J Health Behav*. 1996;20:364–371.
75. Lerman C, Schnoll RA, Hawk LW Jr., et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med*. 2015;3(2):131–138. [http://dx.doi.org/10.1016/S2213-2600\(14\)70294-2](http://dx.doi.org/10.1016/S2213-2600(14)70294-2).
76. Levine MD, Perkins KA, Kalarchian MA, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. *Arch Intern Med*. 2010;170(6):543–550. <http://dx.doi.org/10.1001/archinternmed.2010.33>.
77. Marley JV, Atkinson D, Kitaura T, et al. The Be Our Ally Beat Smoking (BOABS) study, a randomised controlled trial of an intensive smoking cessation intervention in a remote aboriginal Australian health care setting. *BMC Public Health*. 2014;14:32. <http://dx.doi.org/10.1186/1471-2458-14-32>.
78. Martin JE, Calfas KJ, Patten CA, et al. Prospective evaluation of three smoking interventions in 205 recovering alcoholics: one-year results of Project SCRAP-Tobacco. *J Consult Clin Psychol*. 1997;65(1):190–194. <http://dx.doi.org/10.1037/0022-006X.65.1.190>.
79. McCarthy DE, Piasecki TM, Lawrence DL, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. *Nicotine Tob Res*. 2008;10(4):717–729. <http://dx.doi.org/10.1080/14622200801968343>.
80. McDowell I, Mothersill K, Rosser W, Hartman R. A randomized trial of three approaches to smoking cessation. *Can Fam Physician*. 1985;31:845–851.
81. Miguez MC, Vazquez FL, Becona E. Effectiveness of telephone contact as an adjunct to a self-help program for smoking cessation: a randomized controlled trial in Spanish smokers. *Addict Behav*. 2002;27(1):139–144. [http://dx.doi.org/10.1016/S0306-4603\(00\)00166-0](http://dx.doi.org/10.1016/S0306-4603(00)00166-0).
82. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an 42 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. *Clin Ther*. 2007;29(6):1040–1056. <http://dx.doi.org/10.1016/j.clinthera.2007.06.012>.
83. Niaura R, Abrams DB, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD. Cue exposure treatment for smoking relapse prevention: a controlled clinical trial. *Addiction*. 1999;94(5):685–695. <http://dx.doi.org/10.1046/j.1360-0443.1999.9456856.x>.
84. Niaura R, Goldstein MG, Abrams DB. Matching high- and low-dependence smokers to self-help treatment with or without nicotine

- replacement. *Prev Med*. 1994;23(1):70–77. <http://dx.doi.org/10.1006/pmed.1994.1010>.
85. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. *Curr Med Res Opin*. 2008;24(7):1931–1941. <http://dx.doi.org/10.1185/03007990802177523>.
 86. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. *Arch Intern Med*. 2006;166(15):1561–1568. <http://dx.doi.org/10.1001/archinte.166.15.1561>.
 87. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med*. 2006;166(15):1571–1577. <http://dx.doi.org/10.1001/archinte.166.15.1571>.
 88. Park AH, Lee SJ, Oh SJ. The effects of a smoking cessation programme on health-promoting lifestyles and smoking cessation in smokers who had undergone percutaneous coronary intervention. *Int J Nurs Pract*. 2015;21(2):107–117. <http://dx.doi.org/10.1111/ijn.12230>.
 89. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double blind, placebo-controlled study of transdermal. Nicotine patch for smoking cessation. *J Formos Med Assoc*. 1998;97(8):547–551.
 90. Piper ME, Federman EB, McCarthy DE, et al. Efficacy of bupropion alone and in combination with nicotine gum. *Nicotine Tob Res*. 2007;9(9):947–954. <http://dx.doi.org/10.1080/14622200701540820>.
 91. Pirie PL, McBride CM, Hellerstedt W, et al. Smoking cessation in women concerned about weight. *Am J Public Health*. 1992;82(9):1238–1243. <http://dx.doi.org/10.2105/AJPH.82.9.1238>.
 92. Pisinger C, Glumer C, Toft U, et al. High risk strategy in smoking cessation is feasible on a population-based level. The Inter99 study. *Prev Med*. 2008;46(6):579–584. <http://dx.doi.org/10.1016/j.ypmed.2008.02.026>.
 93. Pollak KI, Lyna P, Bilheimer AK, et al. Efficacy of a couple-based randomized controlled trial to help Latino fathers quit smoking during pregnancy and postpartum: the Parejas trial. *Cancer Epidemiol Biomarkers Prev*. 2015;24(2):379–385. <http://dx.doi.org/10.1158/1055-9965.EPI-14-0841>.
 94. Prapavessis H, Cameron L, Baldi JC, et al. The effects of exercise and nicotine replacement therapy on smoking rates in women. *Addict Behav*. 2007;32(7):1416–1432. <http://dx.doi.org/10.1016/j.addbeh.2006.10.005>.
 95. Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. *Tob Control*. 1995;4:231–235. <http://dx.doi.org/10.1136/tc.4.3.231>.
 96. Reid RD, Pipe A, Dafoe WA. Is telephone counselling a useful addition to physician advice and nicotine replacement therapy in helping patients to stop smoking? A randomized controlled trial. *CMAJ*. 1999;160(11):1577–1581.
 97. Richmond RL, Kehoe L, de Almeida Neto AC. Effectiveness of a 24-hour transdermal nicotine patch in conjunction with a cognitive behavioural programme: one year outcome. *Addiction*. 1997;92(1):27–31.
 98. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation*. 2010;121(2):221–229. <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.869008>.
 99. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. *Am J Med*. 2006;119(12):1080–1087. <http://dx.doi.org/10.1016/j.amjmed.2006.04.024>.
 100. Robinson LA, Vander Weg MW, Riedel BW, Klesges RC, McLain-Allen B. “Start to stop”: results of a randomised controlled trial of a smoking cessation programme for teens. *Tob Control*. 2003;12(suppl 4):26–33. http://dx.doi.org/10.1136/tc.12.suppl_4.iv26.
 101. Rovina N, Nikoloutsou I, Katsani G, et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. *Ther Adv Respir Dis*. 2009;3(6):279–287. <http://dx.doi.org/10.1177/1753465809350653>.
 102. Russell MA, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. *BMJ*. 1993;306(6888):1308–1312. <http://dx.doi.org/10.1136/bmj.306.6888.1308>.
 103. Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. *Arch Intern Med*. 1993;153(16):1881–1890. <http://dx.doi.org/10.1001/archinte.1993.00410160041003>.
 104. Scherphof CS, Eijnden R, Engels R, Vollebergh WAM. Long-term efficacy of nicotine replacement therapy for smoking cessation in adolescents: a randomized controlled trial. *Drug Alcohol Depend*. 2014;140:217–220. <http://dx.doi.org/10.1016/j.drugalcdep.2014.04.007>.
 105. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addict Behav*. 1983;8(3):253–261. [http://dx.doi.org/10.1016/0306-4603\(83\)90020-5](http://dx.doi.org/10.1016/0306-4603(83)90020-5).
 106. Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction*. 1995;90(12):1671–1682. <http://dx.doi.org/10.1111/j.1360-0443.1995.tb02837.x>.
 107. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction*. 1996;91(9):1293–1306. <http://dx.doi.org/10.1111/j.1360-0443.1996.tb03616.x>.
 108. Schuck K, Bricker JB, Otten R, Kleinjan M, Brandon TH, Engels RC. Effectiveness of proactive quitline counselling for smoking parents recruited through primary schools: results of a randomized controlled trial. *Addiction*. 2014;109(5):830–841. <http://dx.doi.org/10.1111/add.12485>.
 109. Segnan N, Ponti A, Battista RN, et al. A randomized trial of smoking cessation interventions in general practice in Italy. *Cancer Causes Control*. 1991;2(4):239–246. <http://dx.doi.org/10.1007/BF00052140>.
 110. Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med*. 2002;162(11):1267–1276. <http://dx.doi.org/10.1001/archinte.162.11.1267>.
 111. Shoptaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. *Addiction*. 2002;97(10):1317–1328; discussion 1325. <http://dx.doi.org/10.1046/j.1360-0443.2002.00221.x>.
 112. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J. Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. *Am J Med*. 2003;114(7):555–562. [http://dx.doi.org/10.1016/S0002-9343\(03\)00081-0](http://dx.doi.org/10.1016/S0002-9343(03)00081-0).
 113. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. *Arch Intern Med*. 2004;164(16):1797–1803. <http://dx.doi.org/10.1001/archinte.164.16.1797>.
 114. Slama K, Redman S, Perkins J, Reid AL, Sanson-Fisher RW. The effectiveness of two smoking cessation programmes for use in general practice: a randomised clinical trial. *BMJ*. 1990;300(6741):1707–1709. <http://dx.doi.org/10.1136/bmj.300.6741.1707>.
 115. Smith PM, Corso L, Brown KS, Cameron R. Nurse case-managed tobacco cessation interventions for general hospital patients: results of a randomized clinical trial. *Can J Nurs Res*. 2011;43(1):98–117.
 116. Smith SS, Jorenby DE, Fiore MC, et al. Strike while the iron is hot: can stepped-care treatments resurrect relapsing smokers? *J Consult Clin Psychol*. 2001;69(3):429–439. <http://dx.doi.org/10.1037/0022-006X.69.3.429>.
 117. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. *Lancet*. 1992;340(8815):324–329. [http://dx.doi.org/10.1016/0140-6736\(92\)91403-U](http://dx.doi.org/10.1016/0140-6736(92)91403-U).

118. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. *Chest*. 2011;139(3):591–599. <http://dx.doi.org/10.1378/chest.10-0865>.
119. Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. *Eur Respir J*. 2012;40(3):548–554. <http://dx.doi.org/10.1183/09031936.00155811>.
120. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. *Chest*. 2006;130(2):334–342. <http://dx.doi.org/10.1378/chest.130.2.334>.
121. Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. *Eur Respir J*. 2000;16(4):717–722. <http://dx.doi.org/10.1034/j.1399-3003.2000.16d25.x>.
122. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. *JAMA*. 1993;269(10):1268–1271. <http://dx.doi.org/10.1001/jama.1993.03500100066029>.
123. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. *N Engl J Med*. 1991;325(5):311–315. <http://dx.doi.org/10.1056/NEJM199108013250503>.
124. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. *Eur Respir J*. 1999;13(2):238–246. <http://dx.doi.org/10.1034/j.1399-3003.1999.13b04.x>.
125. Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. *J Intern Med*. 2003;254(2):184–192. <http://dx.doi.org/10.1046/j.1365-2796.2003.01185.x>.
126. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. *Eur Heart J*. 2003;24(10):946–955. [http://dx.doi.org/10.1016/S0195-668X\(03\)00003-4](http://dx.doi.org/10.1016/S0195-668X(03)00003-4).
127. Van Schayck CP, Kaper J, Wagena EJ, Wouters EF, Severens JL. The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. *Addiction*. 2009;104(12):2110–2117. <http://dx.doi.org/10.1111/j.1360-0443.2009.02723.x>.
128. Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches linking hospital to the community. *J Pharm Pract Res*. 2002;32(1):57–62. <http://dx.doi.org/10.1002/jppr200232157>.
129. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction*. 2000;95(suppl 2):1161–1171. <http://dx.doi.org/10.1046/j.1360-0443.2000.95811613.x>.
130. Ward KD, Asfar T, Al Ali R, et al. Randomized trial of the effectiveness of combined behavioral/pharmacological smoking cessation treatment in Syrian primary care clinics. *Addiction*. 2013;108(2):394–403. <http://dx.doi.org/10.1111/j.1360-0443.2012.04048.x>.
131. Wiggers LC, Smets EM, Oort FJ, et al. The effect of a minimal intervention strategy in addition to nicotine replacement therapy to support smoking cessation in cardiovascular outpatients: a randomized clinical trial. *Eur J Cardiovasc Prev Rehabil*. 2006;13(6):931–937. <http://dx.doi.org/10.1097/hjr.0b013e328010f263>.
132. Williams KE, Reeves KR, Billing Jr., Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. *Curr Med Res Opin*. 2007;23(4):793–801. <http://dx.doi.org/10.1185/030079907X182185>.
133. Wong J, Abrishami A, Yang Y, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. *Anesthesiology*. 2012;117(4):755–764. <http://dx.doi.org/10.1097/ALN.0b013e3182698b42>.
134. Zellweger JP, Boelsckei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. Bupropion SR vs placebo for smoking cessation in health care professionals. *Am J Health Behav*. 2005;29(3):240–249. <http://dx.doi.org/10.5993/AJHB.29.3.5>.
135. Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A. A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. *Addiction*. 2008;103(12):2024–2031. <http://dx.doi.org/10.1111/j.1360-0443.2008.02348.x>.
136. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. *Cochrane Database Syst Rev*. 2014;1:CD000031. <http://dx.doi.org/10.1002/14651858.cd000031.pub4>.
137. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev*. 2012;4:CD006103. <http://dx.doi.org/10.1002/14651858.cd006103.pub6>.
138. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. *Cochrane Database Syst Rev*. 2013;5:CD000165. <http://dx.doi.org/10.1002/14651858.cd000165.pub4>.
139. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. *Cochrane Database Syst Rev*. 2013;8:CD002850. <http://dx.doi.org/10.1002/14651858.cd002850.pub3>.
140. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. *Cochrane Database Syst Rev*. 2005;2:CD001007. <http://dx.doi.org/10.1002/14651858.cd001007.pub2>.
141. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. *Cochrane Database Syst Rev*. 2005;2:CD001292. <http://dx.doi.org/10.1002/14651858.cd001292.pub2>.
142. Gorber SC, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. *Nicotine Tob Res*. 2009;11(1):12–24. <http://dx.doi.org/10.1093/ntr/ntn010>.
143. Mottillo S, Filion KB, Bélisle P, et al. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. *Eur Heart J*. 2009;30(6):718–730. <http://dx.doi.org/10.1093/eurheartj/ehn552>.

Appendix

Supplementary data

Supplementary data associated with this article can be found at <http://dx.doi.org/10.1016/j.amepre.2016.07.011>.